1. HOME
2. Research Insight
3. Johnson & Johnson (US) and Baxter International (US) are Leading Players in the Hemostats Market

The hemostats market is valued at an estimated USD 2.7 billion in 2023 and is projected to reach USD 3.7 billion by 2028 at a CAGR of 6.7% during the forecast period. Market growth is largely driven by the increasing number of surgical procedures, heightened emphasis on research and development, a growing occurrence of sports-related injuries, and an increased focus on managing blood loss effectively during surgeries.

The key players in hemostats market are Johnson & Johnson (US), Baxter International (US), Pfizer Inc. (US), B. Braun SE (Germany), Becton, Dickinson and Company (US), Teleflex Incorporated (US), Medtronic Plc (Ireland), Hemostasis, LLC (US), Stryker Corporation (US), Integra LifeSciences (US), Advanced Medical Solutions Group Plc (UK), Samyang Holdings Corporation (South Korea), Marine Polymer Technologies, Inc. (US), GELITA MEDICAL GmbH (Germany), Dilon Technologies, Inc. (US), Betatech Medical (Turkey), Meril Life Sciences Pvt. Ltd. (India), BioCer Entwicklungs-GmbH (Germany), Unilene (US), Katsan Medical Devices (Turkey), Tricol Biomedical (US), 3-D Matrix Medical Technology (Japan), Hemostat Medical GmbH (Germany), Medtrade Products Limited (UK), and Altaylar Medical (Turkey).

To know about the assumptions considered for the study download the pdf brochure

Johnson & Johnson (US) maintained a dominant position in the hemostats market in 2022. The company’s strong distribution networks spanning North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa have contributed to its sustained leadership in the market. The company has a robust portfolio of hemostats, with a very strong presence in the oxidized regenerated cellulose-based hemostats segment. SURGICEL is the company’s major brand for hemostatic agents. With a significant number of subsidiaries operating under Johnson & Johnson globally, the company further seeks to strengthen its presence through strategies such as expansions, approvals, and product launches. In March 2020, Ethicon announced the strategic regional launch of the SURGICEL Powder Absorbable Hemostat in Australia, New Zealand, and Thailand. These strategic initiatives enable Johnson & Johnson to secure a larger market share and strengthen its position in the hemostats market.

In 2022, Baxter International (US) held a significant market share in the hemostats market. The company’s leading position can be attributed to its robust sales and distribution networks, which effectively promote its products across various countries. It has a widespread presence across 100 countries through direct and indirect sales channels. The company consistently invests in R&D, which enables it to launch innovative products in the market. Furthermore, Baxter implements both organic and inorganic strategies, such as product launches and acquisitions, to further strengthen its standing in the hemostats market.

Pfizer Inc. (US), a prominent player in the global hemostats market, secured a significant market share in the the hemostats market in 2022. The company sells its products in about 125 countries across North America, Latin America, Europe, the Middle East, Africa, and the Asia Pacific. The company’s strong presence in the US serves as a foundation for expanding its operations in emerging markets, thereby strengthening its geographical reach. The growing adoption of foam-based hemostats helps the company to generate significant revenues from its hemostat offerings.

Related Reports:

Hemostats Market by Type (Thrombin, Oxidized Regenerated Cellulose, Combination, Gelatin, Collagen), Formulation (Matrix & Gel, Sheet & Pad, Sponge, Powder), Application (Orthopedic, Neurological, Cardiovascular Surgery), Region - Global Forecast to 2028

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]